Pages that link to "Q38129331"

The following pages link to Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. (Q38129331):

Displaying 42 items.

• Biomarkers and Targeted Therapy in Pancreatic Cancer (Q26752755) (← links)
• Prognostic and predictive markers in pancreatic adenocarcinoma (Q26771965) (← links)
• Neoadjuvant therapy for pancreas cancer: past lessons and future therapies (Q27004292) (← links)
• Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward (Q33624574) (← links)
• Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. (Q34234101) (← links)
• Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis. (Q34547888) (← links)
• MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. (Q34704824) (← links)
• Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis (Q35110096) (← links)
• Expression and diagnostic value of HE4 in pancreatic adenocarcinoma (Q35138972) (← links)
• Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study (Q35152701) (← links)
• Protein glycosylation in cancer (Q35413473) (← links)
• GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma (Q35552067) (← links)
• Proteomics analysis of bodily fluids in pancreatic cancer (Q35920900) (← links)
• Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. (Q36042474) (← links)
• Glypican-1 identifies cancer exosomes and detects early pancreatic cancer (Q36781050) (← links)
• A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection (Q36998188) (← links)
• Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma (Q37327988) (← links)
• Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers (Q37693706) (← links)
• Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma (Q37707027) (← links)
• Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture (Q37716406) (← links)
• Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy (Q37721680) (← links)
• Biomarkers for early diagnosis of pancreatic cancer (Q38265405) (← links)
• The need for effective pancreatic cancer detection and management: a biomarker-based strategy (Q38591066) (← links)
• Tumour-associated antigens and their anti-cancer applications (Q38725552) (← links)
• Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma. (Q39108676) (← links)
• Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma (Q41412659) (← links)
• Clinical data combined with radiological imaging improves the accuracy of TNM staging of pancreatic body and tail adenocarcinoma (Q42373823) (← links)
• Upregulated exosomic miR‑23b‑3p plays regulatory roles in the progression of pancreatic cancer (Q44031799) (← links)
• Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma. (Q46296450) (← links)
• Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients (Q47679320) (← links)
• Pancreatic cancer and associated exosomes (Q50075097) (← links)
• Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer (Q50217905) (← links)
• Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer (Q50579768) (← links)
• Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. (Q51697993) (← links)
• Standardized uptake value on positron emission tomography/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer. (Q52991088) (← links)
• Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. (Q53096947) (← links)
• Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma (Q57157498) (← links)
• Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer (Q58605578) (← links)
• Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. (Q64890083) (← links)
• Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer (Q86990644) (← links)
• Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring (Q88726660) (← links)
• Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer (Q89579545) (← links)